Last Updated: November 21, 2026

Details for Patent: 4,031,244

« Back to Dashboard


Summary for Patent: 4,031,244
Title:Pharmaceutical compositions containing a 1-(2,6-dimethyl-phenoxy)-2-amino-alkane and method of use
Abstract:Pharmaceutical compositions containing as an active ingredient a compound of the formula wherein R is hydrogen or alkyl of 1 to 3 carbon atoms, and R1 is hydrogen or methyl, or a non-toxic, pharmacologically acceptable acid addition salt thereof; and a method of using the same as anticonvulsives and antiarrhythmics.
Inventor(s):Herbert Koppe, Karl Zeile, Werner Kummer, Helmut Stahle, Peter Danneberg
Assignee: Boehringer Ingelheim GmbH
Application Number:US05/653,296
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

US Drug Patent 4,031,244: Scope, Claims, Expiration, and Mexiletine Patent Landscape

US Patent 4,031,244 covers pharmaceutical compositions and therapeutic use of a class of substituted phenoxyalkylamines with anticonvulsant or antiarrhythmic activity. Its principal commercial compound is mexiletine, chemically 1-(2,6-dimethylphenoxy)-2-aminopropane, usually administered as mexiletine hydrochloride. The patent issued on June 21, 1977, and its 17-year US patent term expired on June 21, 1994. It no longer creates a US patent barrier to generic mexiletine products.

The patent has two claim groups:

  1. Composition claims covering dosage units containing the claimed active compounds or pharmacologically acceptable acid-addition salts.
  2. Method claims covering administration of those compounds to suppress convulsions or alleviate cardiac arrhythmia.

The claims are chemically broad at the genus level but commercially narrow in practical relevance because the patent has expired.

What patent is US 4,031,244?

US Patent 4,031,244 is a pre-1995 US drug patent directed to substituted phenoxyalkylamines. The patent claims pharmaceutical compositions and treatment methods using racemic or optically active compounds represented by the disclosed formula.[1]

Item Information
US patent 4,031,244
Issue date June 21, 1977
Patent type Pharmaceutical composition and method-of-treatment patent
Principal commercial compound Mexiletine
Chemical name 1-(2,6-dimethylphenoxy)-2-aminopropane
Commercial salt Mexiletine hydrochloride
Claimed activity Anticonvulsant and antiarrhythmic
US patent term 17 years from issue for this pre-1995 patent
US expiration June 21, 1994
Current status Expired

The patent is important historically because claim 2 directly covers mexiletine in racemic or optically active form, including acceptable acid-addition salts.

What compounds does US 4,031,244 cover?

The independent chemical formula covers a phenoxyalkylamine framework containing:

  • A 2,6-dimethyl-substituted phenoxy group.
  • An amino-substituted alkyl side chain.
  • Variable substituents designated R and R1.
  • R as hydrogen or a C1-C3 alkyl group.
  • R1 as hydrogen or methyl.
  • Racemic and optically active forms.
  • Non-toxic, pharmacologically acceptable acid-addition salts.

The claimed structure is substantially broader than mexiletine alone. Claim 1 covers the genus, while claims 2 through 4 identify specific homologs.

Which compounds are specifically claimed?

Claim Specific compound Commercial relevance
1 Genus of substituted phenoxyalkylamines Broad chemical and therapeutic scope
2 1-(2',6'-dimethylphenoxy)-2-aminopropane Mexiletine
3 1-(2',6'-dimethylphenoxy)-2-aminopentane Non-commercial or limited commercial relevance
4 1-(2',6'-dimethylphenoxy)-2-aminohexane Non-commercial or limited commercial relevance
5 Method using the genus compounds Anticonvulsant or antiarrhythmic treatment
6 Method using mexiletine Direct method-of-use coverage for mexiletine
7 Method using the pentane analog Specific homolog
8 Method using the hexane analog Specific homolog

The patent does not claim every antiarrhythmic compound, every local anesthetic, or every phenoxyamine. The molecule must fall within the specified structural formula.

How should the composition claims be interpreted?

Claims 1 through 4 are pharmaceutical composition claims. They require a pharmacodynamic dosage unit composition containing:

  1. An inert pharmaceutical carrier.
  2. An effective anticonvulsant or antiarrhythmic amount of the claimed compound or salt.

The phrase “consisting essentially of” limits the composition more than “comprising” but less than “consisting of.” It generally permits excipients that do not materially alter the basic and novel characteristics of the claimed composition. Conventional capsule, tablet, powder, or liquid excipients would ordinarily be evaluated under that standard.

The claims require a dosage-unit composition rather than merely the isolated molecule. A claim directed solely to the chemical compound would have a different scope. Here, the claimed product is a pharmaceutical dosage form containing the active compound and an inert carrier.

What salt forms are covered?

The claims expressly cover non-toxic, pharmacologically acceptable acid-addition salts. Mexiletine hydrochloride is the commercially relevant example.

The salt language may cover salts formed with suitable inorganic or organic acids, provided the resulting salt is pharmacologically acceptable and falls within the claim. The claim does not automatically cover:

  • Covalent prodrugs.
  • Derivatives that alter the claimed molecular structure.
  • Non-pharmacological salts.
  • Formulations lacking the claimed active compound.
  • Products containing a different therapeutic molecule outside the formula.

What do the method-of-use claims cover?

Claims 5 through 8 cover administering the compounds to a warm-blooded animal in need of treatment. The stated therapeutic purposes are:

  • Suppression of convulsions.
  • Alleviation of cardiac arrhythmia.

The claims do not specify a particular dose, route, treatment duration, disease subtype, or formulation. This gives the method claims broad therapeutic language within the boundaries of the claimed compounds and stated indications.

For mexiletine, claim 6 is the direct species claim. It covers administering racemic or optically active 1-(2,6-dimethylphenoxy)-2-aminopropane, or an acceptable acid-addition salt, at an effective anticonvulsant or antiarrhythmic dose.

The method claims do not cover every use of mexiletine. Uses outside convulsion suppression and cardiac-arrhythmia treatment would require separate claim analysis. The claims also do not independently establish regulatory approval for any indication.

What patent protects mexiletine?

US 4,031,244 is the principal patent identified from the supplied claims that directly protects mexiletine as a composition and as a treatment method.

Mexiletine is the compound covered by claim 2 and the corresponding method is covered by claim 6. The patent’s protection can be summarized as follows:

Protection category Covered by US 4,031,244? Scope
Mexiletine free base Yes Claim 2 and claim 6
Mexiletine hydrochloride Yes Express acid-addition-salt language
Racemic mexiletine Yes Expressly recited
Optically active mexiletine Yes Expressly recited
Capsule containing mexiletine Potentially yes If it satisfies the dosage-unit and carrier limitations
Tablet containing mexiletine Potentially yes Same composition analysis
Specific extended-release formulation Not expressly claimed No formulation technology is recited
Manufacturing process Not claimed in the supplied claims No process limitation appears
Specific dose regimen Not claimed No dosing schedule appears
Non-cardiac use Not expressly claimed Method language is anticonvulsant or antiarrhythmic

When did US 4,031,244 lose exclusivity?

The patent expired on June 21, 1994, based on the 17-year term applicable to US patents issued before the 1995 patent-term transition.[2] The expiration date is more than three decades in the past.

No current patent-term extension or pediatric extension should be attributed to this patent. The patent predates the modern patent-term-restoration framework, and its term was governed by the pre-1995 issue-date rule.

Milestone Date
Patent issued June 21, 1977
17-year patent term ends June 21, 1994
Current status Expired
Generic patent barrier from this patent None

Because the patent expired before the modern Hatch-Waxman litigation period became commercially significant for many products, current generic applicants do not need to overcome an unexpired claim in US 4,031,244.

What is the FDA regulatory status of mexiletine?

Mexiletine hydrochloride is an FDA-approved antiarrhythmic drug. The product is marketed in the United States in oral capsule formulations, including generic products. FDA labeling identifies mexiletine hydrochloride as a Class 1B antiarrhythmic used for documented ventricular arrhythmias, including sustained ventricular tachycardia, where treatment is considered necessary.[3]

The FDA regulatory position is separate from the expired patent position. FDA approval does not revive an expired patent, and patent expiration does not eliminate the need for an approved abbreviated new drug application or other lawful regulatory pathway.

Is mexiletine a biologic or a small-molecule generic?

Mexiletine is a small-molecule drug. It is not a biologic and therefore does not create a biosimilar pathway under the Public Health Service Act.

Generic manufacturers generally rely on the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The relevant regulatory issues include pharmaceutical equivalence, bioequivalence, labeling, manufacturing controls, and product quality.[4]

What is the Orange Book status of mexiletine?

The FDA Orange Book identifies approved drug products and certain patent and exclusivity information associated with those products.[5] US 4,031,244 is expired and cannot function as a current unexpired Orange Book patent barrier.

The relevant commercial conclusion is:

  • Mexiletine hydrochloride capsules are subject to conventional generic-drug competition.
  • US 4,031,244 does not block ANDA approval through an unexpired patent claim.
  • Any current Orange Book patent entry must be evaluated by product and sponsor, but the 1977 patent itself is no longer enforceable.
  • No biologic reference-product or biosimilar listing is relevant.

Are there Paragraph IV challenges to US 4,031,244?

A Paragraph IV certification is used when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. Because US 4,031,244 expired in 1994, it is not a current Paragraph IV barrier for mexiletine products.

Any historical Paragraph IV activity involving mexiletine would have concerned other listed patents, regulatory exclusivity, or product-specific patents, not the expired enforceable term of US 4,031,244. The expired patent cannot support a current 30-month stay under the Hatch-Waxman framework.

What formulation patents protect mexiletine products?

The supplied claims do not contain a formulation-specific invention. They require an inert pharmaceutical carrier but do not define:

  • Particle size.
  • Release-control polymers.
  • Coating thickness.
  • Dissolution profile.
  • Capsule-shell composition.
  • Manufacturing temperature.
  • Granulation process.
  • Specific excipient ratios.
  • Stability-enhancing agents.

The practical scope is therefore a basic dosage-unit composition. A later formulation patent could, in principle, protect a particular modified-release system, dosage form, or manufacturing process even after the core compound patent expired. Such a later patent would need its own valid priority date, written description, enablement, and non-obviousness support.

No such later formulation claim is present in the eight claims supplied for US 4,031,244.

Does the patent cover manufacturing methods?

No. The supplied claims are directed to compositions and methods of treatment. They do not claim:

  • Chemical synthesis of mexiletine.
  • Resolution of enantiomers.
  • Preparation of mexiletine hydrochloride.
  • Crystallization.
  • Purification.
  • Polymorph control.
  • API manufacturing equipment.
  • Capsule filling.
  • Batch-release testing.

A manufacturer could still face separate process, polymorph, or trade-secret barriers under other rights. Those barriers do not arise from the claims quoted here.

What is the patent litigation and settlement landscape?

US 4,031,244 has no current litigation significance because its patent term expired in 1994. A claim directed to conduct occurring after expiration would generally face a fundamental term problem.

The supplied record does not identify a current US infringement action, Paragraph IV case, or settlement agreement tied to this patent. Any historical litigation involving mexiletine should be separated into three categories:

  1. Patent litigation involving the original compound patent.
  2. Regulatory or labeling disputes involving mexiletine products.
  3. Commercial disputes involving generic manufacturers or distributors.

Only the first category would directly bear on the scope of US 4,031,244.

How strong is the patent estate for mexiletine?

The historical estate was strong against direct commercial use of the claimed molecule during the patent term because claim 2 expressly named mexiletine and claim 6 expressly covered its therapeutic administration.

The current estate is weak from an exclusivity perspective because the core patent is expired.

Risk category Current assessment
Core compound patent No current protection from US 4,031,244
Salt protection Expired with the patent
Racemate protection Expired
Enantiomer protection Expired under the express claim language
Method-of-use protection Expired
Formulation protection in supplied claims None
Manufacturing protection in supplied claims None
Biosimilar risk Not applicable
Generic entry risk Low patent risk; ordinary FDA approval and manufacturing risks remain
Litigation risk from this patent Negligible
Licensing leverage from this patent None based on the expired term

How does mexiletine compare with competing antiarrhythmics?

Mexiletine competes with other antiarrhythmic drugs, including amiodarone, lidocaine, flecainide, propafenone, and sotalol. Its patent position differs from newer branded products because the core molecule has been off patent for decades.

Drug Drug class Patent position relevant to US 4,031,244
Mexiletine Class 1B sodium-channel blocker Core patent expired
Lidocaine Class 1B sodium-channel blocker Separate historical patent estate
Flecainide Class 1C sodium-channel blocker Separate compound and use patents
Propafenone Class 1C sodium-channel blocker Separate patent estate
Amiodarone Class III antiarrhythmic Separate compound, formulation, and use history
Sotalol Class III and beta-blocking activity Separate patent estate

The comparison is therapeutic, not a legal overlap analysis. A competing antiarrhythmic does not infringe US 4,031,244 merely because it has a similar mechanism or indication. The accused product would need to satisfy the patent’s structural limitations or, for a method claim, involve administration of a covered compound.

What are the commercial implications for generic launch?

A generic mexiletine launch does not face US 4,031,244 as an enforceable patent obstacle. The relevant commercial hurdles are instead:

  • FDA approval through the appropriate generic pathway.
  • Demonstration of bioequivalence.
  • Compliance with current good manufacturing practices.
  • Supply of mexiletine hydrochloride API.
  • Control of impurities and degradation products.
  • Consistent capsule strength and dissolution.
  • Pharmacovigilance and labeling compliance.
  • Market access, reimbursement, and supply continuity.

There is no current royalty obligation or license requirement created solely by the expired patent. Any separate licensing obligation would have to arise from a later patent, contract, trademark, manufacturing arrangement, or other right.

Key Takeaways

  • US Patent 4,031,244 covers substituted phenoxyalkylamine pharmaceutical compositions and treatment methods.
  • Claim 2 directly covers mexiletine, including racemic, optically active, and acceptable acid-addition-salt forms.
  • Claim 6 covers therapeutic administration of mexiletine for anticonvulsant or antiarrhythmic treatment.
  • The patent issued June 21, 1977, and expired June 21, 1994.
  • The patent has no current blocking effect on generic mexiletine approval or launch.
  • The supplied claims do not cover a specific formulation, manufacturing process, polymorph, dose regimen, or delivery technology.
  • Mexiletine is an FDA-approved small-molecule drug, not a biologic; biosimilar analysis does not apply.
  • Current commercial risk comes from FDA, manufacturing, supply, and market factors rather than US 4,031,244.

FAQs

Does US Patent 4,031,244 cover mexiletine hydrochloride capsules?

Yes, if the capsule is a dosage-unit composition containing mexiletine hydrochloride and an inert pharmaceutical carrier. That protection expired in 1994.

Is mexiletine still patent protected in the United States?

US 4,031,244 no longer protects mexiletine because it expired on June 21, 1994. Separate later patents would require independent analysis.

Can a generic company launch mexiletine without a license to the original patent owner?

The expired patent does not require a license. The manufacturer still needs FDA approval and must avoid infringement of any separate unexpired rights.

Does the patent cover mexiletine enantiomers?

Yes. The claims expressly include optically active compounds. That protection also expired with the patent.

Does US 4,031,244 cover extended-release mexiletine?

Not specifically. The quoted claims do not recite a release mechanism, polymer system, dissolution profile, or other extended-release limitation.

References

  1. United States Patent No. 4,031,244. (1977, June 21). United States Patent and Trademark Office.
  2. United States Code, Title 35, Section 154. (2024). Patent term.
  3. U.S. Food and Drug Administration. (n.d.). Mexiletine hydrochloride capsule prescribing information. DailyMed.
  4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
  5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 4,031,244

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 4,031,244

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
88950Sep 16, 1966
94024Aug 17, 1967

International Family Members for US Patent 4,031,244

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 288353 ⤷  Start Trial
Austria 289075 ⤷  Start Trial
Austria 291225 ⤷  Start Trial
Switzerland 509250 ⤷  Start Trial
Switzerland 509251 ⤷  Start Trial
Switzerland 509252 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.